Low Molecular Weight Heparin as A Therapeutic Tool for Cancer; Special Emphasis on Breast Cancer

Sumanasekera, Wasana; Nethery, William; Tran, Liem; Pillai, G. K.

doi:10.26717/bjstr.2018.11.002064

Cited by 5 publications

(6 citation statements)

References 66 publications

(130 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect seems to be linked to different synergistic mechanisms, among which are the prevention of cancer-induced hypercoagulation, cancer cell proliferation, apoptosis, and angiogenesis [ 25 ]. Specifically, LMWH expresses anti-angiogenic activity via binding and inhibiting angiogenic growth factors, such as Vascular Endothelial Growth factor (VEGF), and interferes with fibrin formation, resulting in inhibition of cancer metastasis [ 26 ].…”

Section: Biological Mechanisms Of Cancer-related Thrombosismentioning

confidence: 99%

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

et al. 2022

View full text Add to dashboard Cite

Acute thrombotic events can unveil occult cancer, as they are its first manifestation in about 20 to 30% of all cases. Malignancy interacts in an intricate way with the hemostatic system, promoting both thrombosis and bleeding. The main pathway involved in these reactions involves the activation of tumor-associated procoagulant factors, which eventually results in clot formation. The clinical manifestation of cancer-related thrombotic events mainly involves the venous side, and manifests in a broad spectrum of conditions, including unusual sites of venous thrombosis. The selection of patients who have a balanced risk–benefit profile for management of anticoagulation is complex, given individual patient goals and preferences, different prognosis of specific cancers, common comorbidities, potential drug–drug interactions, underweight states, and the competing risks of morbidity and mortality. Anticoagulant treatment in cancer settings is broadly debated, considering the potential application of direct oral anticoagulants in both thromboprophylaxis and secondary prevention, having demonstrated its efficacy and safety compared to conventional treatment. This review aims to provide a brief overview of the pathophysiology and management of cancer-related thrombosis, summarizing the results obtained in recent clinical trials.

show abstract

Section: Biological Mechanisms Of Cancer-related Thrombosismentioning

confidence: 99%

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Furthermore, heparin has immunoregulatory functions as well as it binds to cytokines and growth factors such as tumor necrosis factor (TNF) and extracellular matrix proteins (ECM), thus regulating the leukocytes. [15][16][17] It is believed that LMWH reduces the risk of cancer-associated thrombosis (CAT). 34 However, it is associated with quite severe adverse events, as it is the heparin-induced thrombocytopenia (HIT).…”

Section: Discussionmentioning

confidence: 99%

“…14 Recent studies have shown that LMWH has immunoregulatory functions and leads to immunosuppression. [15][16][17] Regarding this term, an important question arises, namely, whether the LMWH during the postoperative hospitalization of gastrointestinal cancer patients is linked to infection, which the presents study aims to answer.…”

Section: Introductionmentioning

confidence: 99%

Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience 

Nikova¹,

Kyriazi²,

Michalopoulou³

et al. 2020

View full text Add to dashboard Cite

Introduction: Patients with gastrointestinal cancer are at high risk of developing thrombosis and postoperative infection. Antico-agulation therapy for such patients is provided by low molecular weight heparin (LMWH) and elastic stockings. The latter, however, is linked to immunoregulatory activities and immunosuppression in vivo and in vitro. Aim: Therefore, the present study aimed to examine the link between LMWH and infection in patients with gastrointestinal cancer. Materials and methods: The study is a retrospective report of 51 patients operated on at the Second Department of Surgery at Metaxa Cancer Hospital. The sample was divided into groups based on the presence or absence of diabetes and preoperative anticoagu-lation therapy. Afterwards, the data were statistically analysed.  Results: The results of the study show a statistically significant correlation between LMWH and infection. Moreover, the risk of infec-tion increases by 13.3% for each day of heparin intake. The theory of this correlation is explained in detail.  Conclusions: The findings of the present study raise an essential question about postoperative management of cancer patients. How-ever, the study sample size is rather small so further studies with larger sample size are required to give greater credence to results.

show abstract

“…Beyond their anticoagulant action, several experimental evidences have suggested that LMWH could have potential benefits in cancer through multiple mechanisms [79]. Indeed, LMVHs were shown to inhibit CXCL12-mediated cell migration, angiogenesis (by interfering with VEGF, TF-FVIIa activation, fibrin and thrombin), P-and L-selectin-mediated cell adhesion, cell proliferation, tumour invasion, tumour growth and metastasis [79,80].…”

Section: Low-molecular-weight Heparins (Lmwhs) and Cancermentioning

confidence: 99%

Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

Castiglioni

Camera

Sironi

2020

Biochemical Pharmacology

View full text Add to dashboard Cite

Low Molecular Weight Heparin as A Therapeutic Tool for Cancer; Special Emphasis on Breast Cancer

Cited by 5 publications

References 66 publications

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience

Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

Contact Info

Product

Resources

About

Low Molecular Weight Heparin as A Therapeutic Tool for Cancer; Special Emphasis on Breast Cancer

Cited by 5 publications

References 66 publications

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment

Postoperative Low Molecular Weight&nbsp;Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience&nbsp;

Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

Contact Info

Product

Resources

About

Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience